- A phase II, open-labeled, single-arm study of dose-dense paclitaxel plus carboplatin in advanced or recurrent uterine endometrial cancer treatment: a KCOG-G1303, DOENCA trial
-
Hori K, Nishio S, Ushijima K, Kasamatsu Y, Kondo E, Takehara K, Ito K
- KMID: 2526119
- J Gynecol Oncol.
- 2021 Jul;32(4):e64.
- doi: 10.3802/jgo.2021.32.e64
Objective To determine the safety and efficacy of dose-dense (dd) paclitaxel (PTX) and carboplatin (CBDCA) in treating advanced or recurrent endometrial cancer. Methods Women aged 20–75 years with histologically confirmed endometrial cancer, the... -
- CITED
-
- Close
- SHARE
-
- Close
- Frequency and clinical features of deficient mismatch repair in ovarian clear cell and endometrioid carcinoma
-
Tanaka T, Takehara K, Yamashita N, Okazawa-Sakai M, Kuraoka K, Teramoto N, Taguchi K, Yamashiro K, Kato H, Mizunoe T, Suzuki R, Yamamoto D, Ueki A, Saito T
- KMID: 2537914
- J Gynecol Oncol.
- 2022 Sep;33(5):e67.
- doi: 10.3802/jgo.2022.33.e67
Objective To clarify the frequency of deficient mismatch repair (dMMR) in Japanese ovarian cancer patients, we examined microsatellite instability (MSI) status and immunohistochemistry (IHC) subtypes, including endometrioid carcinoma (EMC), clear cell... -
- CITED
-
- Close
- SHARE
-
- Close
- Current status of hereditary breast and ovarian cancer practice among gynecologic oncologists in Japan: a nationwide survey by the Japan Society of Gynecologic Oncology (JSGO)
-
Kobayashi Y, Masuda K, Hiraswa A, Takehara K, Tsuda H, Watanabe Y, Oda K, Nagase S, Mandai M, Okamoto A, Yaegashi N, Mikami M, Enomoto T, Aoki D, Katabuchi H, Working Group on Clinical Practice for Cancer Genomic Medicine and HBOC, Japan Society of Gynecologic Oncology
- KMID: 2537910
- J Gynecol Oncol.
- 2022 Sep;33(5):e61.
- doi: 10.3802/jgo.2022.33.e61
Objective The practices pertaining to hereditary breast and ovarian cancer (HBOC) in Japan have been rapidly changing owing to the clinical development of poly(ADP-ribose) polymerase inhibitors, the increasing availability of companion... -
- CITED
-
- Close
- SHARE
-
- Close
- Risk stratification models for para-aortic lymph node metastasis and recurrence in stage IB–IIB cervical cancer
-
Matsuo K, Shimada M, Saito T, Takehara K, Tokunaga H, Watanabe Y, Todo Y, Morishige , Mikami M, Sugiyama T
- KMID: 2395238
- J Gynecol Oncol.
- 2018 Jan;29(1):e11.
- doi: 10.3802/jgo.2018.29.e11
OBJECTIVE: To examine the surgical-pathological predictors of para-aortic lymph node (PAN) metastasis at radical hysterectomy, and for PAN recurrence among women who did not undergo PAN dissection at radical hysterectomy. METHODS:... -
- CITED
-
- Close
- SHARE
-
- Close
- Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer
-
Takehara K, Matsumoto T, Hamanishi J, Hasegawa K, Matsuura M, Miura K, Nagao S, Nakai H, Tanaka N, Tokunaga H, Ushijima K, Watari H, Yokoyama Y, Kase Y, Sumino S, Suri A, Itamochi H, Takeshima N
- KMID: 2526362
- J Gynecol Oncol.
- 2021 Mar;32(2):e21.
- doi: 10.3802/jgo.2021.32.e21
Objective: The primary objective of this study was to evaluate the safety of niraparib 300 mg/day in Japanese patients with platinum-sensitive, relapsed ovarian cancer in a maintenance setting. Methods: Phase 2,... -
- CITED
-
- Close
- SHARE
-
- Close
- Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer
-
Okamoto A, Kondo E, Nakamura T, Yanagida S, Hamanishi J, Harano K, Hasegawa K, Hirasawa T, Hori K, Komiyama S, Matsuura M, Nakai H, Nakamura H, Sakata J, Tabata T, Takehara K, Takekuma M, Yokoyama Y, Kase Y, Sumino S, Soeda J, Suri A, Aoki D, Sugiyama T
- KMID: 2526354
- J Gynecol Oncol.
- 2021 Mar;32(2):e16.
- doi: 10.3802/jgo.2021.32.e16
Objective: To evaluate the efficacy and safety of niraparib in Japanese women with heavily pretreated ovarian cancer. Methods: This Phase 2 open-label, single-arm study enrolled Japanese women with homologous recombination deficiency-positive... -
- CITED
-
- Close
- SHARE
-
- Close
